Massachusetts General Hospital

As the COVID-19 pandemic limited options for musculoskeletal care by requiring practices to stratify patients based on the urgency of their injury, orthopedic surgeons at Massachusetts General Hospital began converting existing clinical protocols to telemedicine to meet the need for care for a wider range of patients in their practice.

The FDA granted orphan drug designation to CART-ddBCMA, a chimeric antigen receptor T-cell therapy, for the treatment of multiple myeloma, according to a press release from the manufacturer.

The problem of hypertension is a multifaceted one. Many factors contribute to the increasing global burden of hypertension. Cardiology Today asked some of the nation’s leading experts on hypertension to glean their thoughts on the most critical issues facing patients and clinicians in that area.

Low-dose aspirin use appeared associated with significantly lower risk for hepatocellular carcinoma and lower liver-related mortality among patients with chronic viral hepatitis, according to results of a retrospective study published in The New England Journal of Medicine.

The Mark Foundation for Cancer Research presented grants to six early career scientists who are conducting research projects designed to address unmet needs.

Hospitals in the United States implemented new policies based on the severe 2017-2018 influenza season, but experts agree that America’s health care systems would still be seriously challenged by another bad season.

SAN ANTONIO — Anastrozole reduced breast cancer risk by 49% compared with placebo for postmenopausal women at high risk for the disease, according to long-term results of the randomized controlled IBIS-II trial presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — Accelerated partial breast irradiation after surgery appeared as effective as whole breast irradiation for preventing recurrence among patients with early breast cancer, according to 10-year follow-up results from the randomized phase 3 APBI IMRT Florence trial presented at San Antonio Breast Cancer Symposium.

ORLANDO — The use of high-dose post-transplant cyclophosphamide reduced the incidence of severe acute and chronic graft-versus-host disease without affecting risk for relapse among patients undergoing allogeneic hematopoietic stem cell transplant with matched related or unrelated donors, according to results of the randomized phase 3 HOVON-96 study presented during the plenary session of ASH Annual Meeting and Exposition.

Pembrolizumab plus radiotherapy appeared safe and demonstrated encouraging clinical activity among a small cohort of women with poor-prognosis, metastatic triple-negative breast cancer, according to results of a phase 2 trial published in Cancer.